Impact ledger
Teva Pharmaceutical Industries Ltd. (TEVA): the developments shaping its investment case
Follow the evidence affecting Teva Pharmaceutical Industries Ltd.'s financing assumptions. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.
Test assumptions, examine opportunities, and save your research.
Material developments
Evidence affecting valuation assumptions
Each entry names the assumption the evidence touches and how the evidence reads. Direction describes the business mechanism, not a stock-price conclusion.
| Date | Assumption | Direction | Interpretation |
|---|---|---|---|
| 2026-09-11 | wacc | Bullish | Higher cost-of-debt tranche lifts blended WACC. |
| 2026-09-11 | interest_expense | Bullish | High-yield coupon materially raises interest burden. |
| 2026-09-11 | net_debt | Bullish | Sub-IG debt raise increases leverage and net debt. |
Event impact log
12 events mapped to TEVA since 2026-08-26. Evidence through 2026-09-19.
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-09-19 | Teva Highlights Real-World Data Demonstrating UZEDY Superiority in Treatment Continuity | Direct positive impact on UZEDY sales and market share due to demonstrated superior real-world outcomes, potentially leading to increased prescriptions and payer preference. | Bullish | 1-3m | 0.80 |
| 2026-09-19 | Teva presents real-world data showing UZEDY treatment continuity advantage | Improved real-world data for UZEDY could enhance physician prescribing confidence and patient adherence, potentially leading to increased market share and sales volume for the drug. Reduced healthcare costs and ED visits may also appeal to payers, supporting favorable formulary placement. | Bullish | 1-3m | 0.70 |
| 2026-09-19 | Teva real-world data demonstrates UZEDY reduces emergency care and medical costs | Increased market penetration and physician preference for UZEDY due to demonstrated cost-effectiveness and improved patient outcomes, potentially leading to higher sales volume and market share. | Bullish | 3-12m | 0.70 |
| 2026-09-19 | Teva Real-World Data Shows UZEDY Superiority in Schizophrenia Continuity | Direct product competitive advantage and market share gain potential. | Bullish | 1-3m | 0.80 |
| 2026-09-19 | Teva Clinical Evidence Highlights UZEDY Treatment Retention and Cost Reductions | Direct product sales and market share gains due to demonstrated superior efficacy and cost-effectiveness, potentially leading to increased prescriptions and formulary inclusions. | Bullish | 3-12m | 0.80 |
| 2026-09-19 | Teva Real-World Data Shows UZEDY Lowers Emergency Healthcare Utilization | Improved market positioning and formulary access for key product UZEDY, potentially leading to increased sales volume and better pricing power. | Bullish | 1-3m | 0.80 |
| 2026-09-19 | Teva Real-World Study Shows UZEDY Outperforms Long-Acting Injectables | Direct product sales increase due to enhanced market perception and physician preference, potentially leading to increased market share. | Bullish | 1-3m | 0.80 |
| 2026-09-16 | NRx Pharmaceuticals Reports FDA Reclassification of Ketamine Amendment to Minor Amendment | Potential future competition in the generic ketamine market, if NRXP's product is approved. | watch | 3-12m | 0.20 |
| 2026-09-07 | Teva launches EUR and USD senior notes to refinance high-coupon 2028-2029 debt | Direct reduction in interest expense due to refinancing higher-coupon debt with potentially lower-coupon new debt. | Bullish | 1-3m | 0.70 |
| 2026-09-07 | Teva Launches EUR and USD Senior Notes Offering to Redeem 2028-2029 Debt | Direct financial optimization through debt refinancing. | Bullish | 1-3m | 0.70 |
| 2026-09-07 | Teva Launches Multi-Currency Senior Notes to Refinance High-Coupon 2028-2029 Debt | Direct reduction in interest expense and improved debt maturity profile. | Bullish | 1-3m | 0.80 |
| 2026-08-26 | Multiple System Atrophy Drug Pipeline Expands to 24 Clinical Candidates Across 22 Firms | Potential for increased competition in neurological disorder treatments, or opportunities for late-stage development/commercialization partnerships. | watch | 3-12m | 0.40 |
Continue this research
Build your Teva Pharmaceutical Industries Ltd. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.
This ledger is regenerated from Market Ontology's public event pipeline. View the TEVA entity page →